Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection

Bibliography

• CARPENTER CJ, FISCHL MA, HAMMER SM et al.: Antiretro-viral therapy for HIV infection in 1998. JAMA (1998) 280:78–86.
   PubMed Web of Science ®Google Scholar
• GAZZARD BG, MOYLE GJ on behalf of the BHIVAguidelines writing Committee 1998: Revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet (1998) 352:314–316.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Viral resistance patterns selected by antiret-roviral drugs and their potential to guide treatment choice. Exp. Opin. Invest. Drugs (1997) 6:943–964.
   PubMedGoogle Scholar
• CHEN MS, OSHANA SC: Inhibition of HIV reversetranscriptase by 2',3'-dideoxycytidine triphosphate. Biochem. Pharmacol. (1987) 36:4361–4362.
   PubMed Web of Science ®Google Scholar
• BARRY M, MULCAHY F, MERRY C, GIBBONS S, BACK D:Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokin. (1999) 36:289–304.
   PubMed Web of Science ®Google Scholar
• •Guide to drug interactions with ART.
   Google Scholar
• CHANG C-N, SKALSKI V, ZHOU JH, CHENG Y-C: Biochemical pharmacology of (+)- and (-)-2'3'dideoxythiacytidine as antihepatitis B agents. J. Biol. Chem. (1992) 267:22414–22420.
   PubMed Web of Science ®Google Scholar
• LEWIS W, DALAKAS MC: Mitochondrial toxicity of antiviral drugs. Nature Med. (1995) 1:417–422.
   PubMed Web of Science ®Google Scholar
• •Review of principle cause of NA toxicity.
   Google Scholar
• GRAY NM, MARR CLP, PENN CR, CAMERON JM, BETHELL RC: The intracellular phosphorylationdeoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by 11IV-1 reverse transcriptase and human DNA polymerase y. Biochem. Pharmacol. (1995) 50:1043–1051.
   PubMed Web of Science ®Google Scholar
• GAO WY, AGBARIA R, DRISCOLL JS, MITSUYA H:Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2'3'-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. (1994) 269:12633–12638.
   PubMed Web of Science ®Google Scholar
• FALETTO MB, MILLER WH, GARVEY EP, ST CLAIR MH,DALUGE SM, GOOD SS: Unique intracellular activation of the potent anit-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. (1997) 41:1099–1107.
   PubMed Web of Science ®Google Scholar
• MALATY LI, KUPER JJ: Drug interactions of HIV protease inhibitors. Drug Safety (1999) 20:147–169.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ, GAZZARD BG: Current knowledge and future prospects for the use of HIV proteinase inhibi-tors. Drugs (1996) 51:701–712.
   PubMed Web of Science ®Google Scholar
• CAESAR Co-ordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with 11IV-1 infection: the CAESAR trial. Lancet (1997) 349:1413–1421.
   PubMed Web of Science ®Google Scholar
• •Clinical endpoints with triple nucleoside therapy.
   Google Scholar
• KATLAMA C, MURPHY R, JOHNSON V et al.: The Atlantic study:A randomised open-label study comparing two protease inhbitors (PO-sparing antiretroviral strate-gies versus a standard PI-containing regimen. 6th Conference on Retroviruses and Opportunistic Infections. Chicago Jan 31 - Feb 4 (1999). Abstract 18.
   Google Scholar
• •All leading treatment approaches appear similar in low viral load patients over 24 weeks.
   Google Scholar
• STAZEWSKI S, KEISER P, GATHE J et al.: Ziagen/Combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005). 6th Conference on Retroviruses and Opportunistic infections. Chicago Jan 31-Feb 4 (1999). Abstract 20.
   Google Scholar
• •Similarity between abacavir and indinavir in placebo controlled trials.
   Google Scholar
• FISCHL M, GREENBERG S, CLUMECK N et al.: Ziagen (abacavir, ABC, 1592) combined with 3TC & ZDV is highly effective and durable through 48 weeks in 11IV-1 infected antiretroviral therapy naive subjects (CNAA 3003). 6th Conference on Retroviruses and Opportunistic infections. Chicago Jan 31-Feb 4 (1999). Abstract 19.
   Google Scholar
• •Prolonged safety and efficacy of the triple nucleoside approach.
   Google Scholar
• VERNAZZA P, KATLAMA C, CLOTET B et al: Intensifica-tion of stable background (SBG) therapy with abacavir (Ziagen, ABC, 1592): 16 week and preliminary 24 week data. 6th Conference on Retroviruses and Opportunistic Infections. Chicago Jan 31-Feb 4 (1999). Abstract 378.
   Google Scholar
• ROZENBAUM W, DELPHIN N, KATLAMA C et al.: Treatment intensification with Ziagen (abacavir, ABC, 1592) in 11IV-1 infected patients with previous 3TC/ZDV antiretroviral treatment - CNA3009. Abstract 377.
   Google Scholar
• STASZEWSKI S, KATLAMA C, HARRER T et al: Abacavir(ABC, 1592) combination therapy in 11IV-1 infected adults: Durability to 72 weeks. 12th World AIDS Confer-ence. Geneva, Switzerland June 28-July 3 (1998). Abstract 12212.
   Google Scholar
• HENRY K, SHAEFER M, ROSS L et al.: Target (NZTA5005): response to combivir and ziagen given b.i.d. to nucleo-side experienced patients is not affected by the presence of the M184V mutation. 6th Conference on Retroviruses and Opportunistic Infections. Abstract 132.
   Google Scholar
• MOYLE G, WILKINS E, LEEN C, REYNOLDS B, GAZZARD BG: Salvage therapy with abacavir (ABC) + efavirenz (EFV) or nevirapine (NVP) in 11IV-1 infected persons with CD4 cell counts 100/mm3 and prior protease inhibitor (PO therapy. 5th Annual meeting of the British HIV Association. Cambridge March 26–28 (1999). Abstract 027.
   Google Scholar
• FOSTER RH, FAULDS D: Abacavir. Drugs (1998)55:729–738.
   PubMed Web of Science ®Google Scholar
• SULLIVAN AK, NELSON MR, MOYLE GJ, ASBOE D, FRANCIS N, GAZZARD BG: Abacavir hypersensitivity reaction: continuing therapy with corticosteroid and antihistamine cover. AIDS (1998) 12 (Suppl. 4):158.
   Google Scholar
• WALENSKY RP, GOLBERG J, DAILY JP: Anaphylaxis after rechallenge with abacavir. AIDS (1999) 13:999–1000.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ, GAZZARD BG: Risk-benefit assessment of HIV protease inhibitors. Drug Safety (1999):299–321.
   PubMed Web of Science ®Google Scholar
• GAZZARD BG, MOYLE GJ: The role of didanosine in the management of 11IV-1 infection. Antiviral Therapy (1997) 2:135–147.
   PubMedGoogle Scholar
• PORTEGIES P, DE GANS J, LANGE JMA et al.: Declining incidence of AIDS dementia after introduction of zidovudine treatment. Br. Med. J. (19890 229:819–821.
   Google Scholar
• GISLOF EH, PORTEGIES P, HOETELMANS R et al.: Effect of ritonavir (RTV)/saquinavir (SQV) verses RTV/SQV/stavudine (d4T) on cerebrospinal fluid (CSF) HIV-RNA levels:preliminary results. 12th World AIDS Conference. Geneva, Switzerland 28 June-3 July (1998). Abstract 32197.
   Google Scholar
• RUIZ L, VAN LUZEN J, ARNO A et al.: Protease inhibitor containing regimens compared with nucleoside analogues alone in the suppression of persistent 11IV-1 replication in lymphoid tissue. AIDS (1999) 13:F1–F8.
   PubMed Web of Science ®Google Scholar
• FESSEL WJ, HAAS DW, DELAPENHA RA et al: A Phase III, double blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, Sustiva, DMP 266) and indinavir (IDV) versus indinavir in 11IV-1 infected patients receiving nucleoside analogue (NRTO therapy at 24 weeks. 12th World AIDS Conference. Geneva, Switzerland, June 28-July 3 (1998). Abstract 22343.
   Google Scholar
• MILD VAN D, MARTIN G, EYSTER M et al.: Initial effective-ness and tolerability of nelfinavir (NFV) in combina-tion with efavirenz (EFV, Sustiva, DMP 266) in antiretroviral naive and nucleoside analogue experi-enced 11IV-1 infected patients: characterisation in a Phase II, open-label, multicenter study at 16 weeks [DMP 266-024]. 12th World AIDS Conference. Geneva, Switzerland June 28-July 3 (1998): Abstract 22386.
   Google Scholar
• SHIRASAKA T, KAVLICK MF, VENO T et al.: Emergence of human immunodeficiency virus Type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA (1995) 92:2398–2402.
   PubMed Web of Science ®Google Scholar